Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has outperformed the market, with the industry index rising by 1.8% from July 11 to July 18, compared to a 0.7% increase in the Shanghai Composite Index [9][20] - The report highlights significant price increases in TDI, glyphosate, and glufosinate due to supply disruptions and rising demand, particularly in South America [6][31][33] Summary by Sections 1. Core Viewpoints - The basic chemical sector is expected to benefit from supply-side reforms and improved demand due to recent government policies aimed at stabilizing the economy [17] - The report emphasizes the potential for long-term investment in core assets as the profitability of chemical products has likely bottomed out, suggesting a recovery in valuations [17][18] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has shown a year-to-date increase of 10.8%, outperforming both the Shanghai Composite and ChiNext indices by 5.4% and 4.5%, respectively [20][26] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 251 stocks rose while 162 fell during the reporting week, with notable gainers including Shangwei New Materials (+148.8%) and Dongcai Technology (+33.2%) [29][30] 4. Key News and Company Announcements - A fire at Covestro's TDI plant in Germany has led to significant supply disruptions, creating opportunities for price increases in TDI [31][32] - Glyphosate prices have increased to 25,500 CNY per ton, reflecting a 7.16% month-over-month rise, driven by reduced inventory levels [33] - New regulations on glufosinate are expected to constrain supply, potentially leading to price increases as the market adjusts [34]

Core Viewpoint - The article highlights the active cash dividend distribution by listed companies in the context of regulatory encouragement, with a total of 3,679 companies proposing distribution plans for the 2024 fiscal year, including cash dividends totaling 1.64 trillion yuan [1][2]. Group 1: Dividend Distribution - A total of 3,674 companies included cash dividends in their 2024 distribution plans, with a cumulative cash payout of 1.64 trillion yuan [1]. - There are 346 companies that included stock transfers in their distribution plans for 2024 [1]. - The article emphasizes two important dates for investors focused on dividends: the ex-dividend date and the record date, with 3,398 companies having already implemented their distribution plans [1]. Group 2: Companies with Dividend Plans - Among the 13 companies with record dates today, 9 companies have a cash dividend of 1 yuan (after tax) or more per 10 shares, with Weike Technology offering the highest at 6.00 yuan per 10 shares [1][2]. - The companies listed for dividend distribution include: - Weike Technology: 6.00 yuan per 10 shares, latest closing price 83.66 yuan, 5-day increase 30.35% [2]. - Zhejiang Medicine: 3.70 yuan per 10 shares, latest closing price 15.51 yuan, 5-day increase 1.31% [2]. - Hangzhou Bank: 2.80 yuan per 10 shares, latest closing price 16.85 yuan, 5-day decrease 2.94% [2].

Group 1 - The core viewpoint of the news is that the Artemisinin concept sector has seen a significant increase, with a rise of 2.65%, ranking third among concept sectors in terms of growth [1] - Within the Artemisinin concept sector, 10 stocks experienced an increase, with Rundu Co., Ltd. hitting the daily limit, and notable gains from Fosun Pharma, China Resources Sanjiu, and Haizheng Pharmaceutical, which rose by 3.94%, 3.10%, and 2.71% respectively [1][2] - The sector attracted a net inflow of 369 million yuan from main funds, with seven stocks receiving net inflows, and five stocks seeing inflows exceeding 30 million yuan [2] Group 2 - The leading stock in terms of net inflow was Rundu Co., Ltd., which saw a net inflow of 145 million yuan, followed by Fosun Pharma, Haizheng Pharmaceutical, and Zhejiang Medicine with net inflows of 101 million yuan, 53.91 million yuan, and 50.35 million yuan respectively [2][3] - In terms of fund inflow ratios, Rundu Co., Ltd., Zhejiang Medicine, and China Resources Sanjiu had the highest ratios, with net inflow rates of 42.20%, 11.87%, and 8.44% respectively [3] - The trading performance of the top stocks in the Artemisinin concept sector showed significant turnover rates, with Rundu Co., Ltd. at 10.26%, Fosun Pharma at 2.30%, and Haizheng Pharmaceutical at 5.63% [3]

2024年年度权益分派实施公告 证券代码：600216 证券简称：浙江医药 公告编号：2025-029 浙江医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 Ａ股每股现金红利0.37元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/18 | － | 2025/7/21 | 2025/7/21 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 7 号— —回购股份》等有关规定，公司股份回购专用证券账户持有的公司股 ...

Core Viewpoint - Zhejiang Pharmaceutical Co., Ltd. is implementing a differentiated dividend distribution plan for the fiscal year 2024, which has been approved by the board of directors and the annual general meeting of shareholders [5][6]. Group 1: Reasons for Differentiated Dividend - The company held its 10th fourth board meeting on April 14, 2025, where it approved a share repurchase plan through centralized bidding [5]. - A special securities account for share repurchase has been established, and as of the application date for the differentiated dividend, the account holds 9,619,400 shares that will not participate in profit distribution [5][6]. Group 2: Dividend Distribution Plan - The annual general meeting on June 25, 2025, approved a profit distribution plan, which includes a cash dividend of 0.37 yuan per share (tax included) based on the total share capital [5][6]. - The total share capital is 961,637,750 shares, and the shares held in the repurchase account will not be included in the profit distribution [5]. Group 3: Calculation Basis for Dividend - The ex-dividend reference price is calculated using the formula: (previous closing price - cash dividend) ÷ (1 + change in circulating shares ratio) [6]. - Based on the closing price of 15.14 yuan per share on July 1, 2025, the actual ex-dividend reference price is calculated to be 14.77 yuan [6]. Group 4: Conclusion - The legal opinion confirms that the differentiated dividend distribution complies with relevant laws and regulations, and does not harm the interests of the company or all shareholders [6].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600216 证券简称：浙江医药 公告编号：2025-029 浙江医药股份有限公司 ? 每股分配比例 Ａ股每股现金红利0.37元（含税） ? 相关日期 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放日 Ａ股 2025/7/18 － 2025/7/21 2025/7/21 ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东大会审议通过。 二、 分配方案 流通股份变动比例=（参与分配的股本总数×实际分派的送转比例）÷总股本， 因本次权益分派无送转股和转增分配，所以送转比例为 0，流通股份变动比例为 0。 综上，本次权益分派除权（息）参考价格=（前收盘价格-每股现金红利）÷ （1+流通股份变动比例）=（前收盘价格-0.3663）÷（1+0）=（前收盘价格-0.3663） 元/股。 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-030 浙江医药股份有限公司关于 2024 年年度 权益分派实施后调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 调整前回购股份数量区间（以调整前的回购股份价格上限计算）： 4,800,769 股至 9,601,536 股。 调整后回购股份数量区间（以调整后的回购股份价格上限计算）： 4,887,586 股至 9,775,171 股。 一、 回购股份的基本情况 浙江医药股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开第十 届四次董事会会议，审议通过了《关于以集中竞价交易方式回购股份方案的议案》， 同意公司使用自有资金或自筹资金以集中竞价交易方式回购公司股份，用于后续 实施员工持股计划或股权激励，回购价格不超过人民币 20.83 元/股（含），回购 资金总额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购期限自 董事会审议通过回购股份方案之日起不超过 12 个月，即 2025 年 4 ...

国浩律师（上海）事务所 关 于 浙江医药股份有限公司 差异化分红事项 之 法 律 意 见 书 中国上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52433320 网址/Website:http://www.grandall.com.cn 1 国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 法律意见书 目 录 | 第一节 律师声明事项 . | | --- | | 第二节 正 文 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 4 | | 一、本次差异化分红的原因…………………………………………………………………………………………………………………………………………………………… ...

[Core Performance Forecast Data](index=1&type=section&id=I.%E3%80%81Current%20Period%20Performance%20Forecast) The company forecasts H1 2025 net profit attributable to shareholders to be **RMB 600-720 million**, a **90.28%-128.33% increase**, with non-recurring adjusted net profit at **RMB 590-708 million**, up **86.27%-123.53%** H1 2025 Performance Forecast | Metric | Estimated Amount (RMB Million) | YoY Growth | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 600.00 - 720.00 | 90.28% - 128.33% | | **Net Profit After Non-Recurring Items** | 590.00 - 708.00 | 86.27% - 123.53% | [Prior Period Performance Review](index=1&type=section&id=II.%E3%80%81Prior%20Period%20Operating%20Performance%20and%20Financial%20Position) In H1 2024, the company reported **RMB 315.33 million** in net profit attributable to shareholders, **RMB 316.74 million** in non-recurring adjusted net profit, and **RMB 0.33** in basic earnings per share, serving as the basis for this forecast H1 2024 (Prior Period) Performance | Metric | Amount (RMB) | | :--- | :--- | | Total Profit | 334.59 million | | Net Profit Attributable to Parent Company Shareholders | 315.33 million | | Net Profit After Non-Recurring Items | 316.74 million | | Earnings Per Share | 0.33 | [Analysis of Performance Increase Drivers](index=2&type=section&id=III.%E3%80%81Primary%20Reasons%20for%20Current%20Period%20Performance%20Increase) The significant performance increase is primarily driven by the company's life nutrition products segment, which saw robust market demand and rising sales prices for its main products, boosting overall revenue and profit - The primary driver for performance growth is the life nutrition products segment, with increased market demand and sales prices for its leading products compared to the prior year, leading to higher sales revenue[6](index=6&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=IV.%E3%80%81Risk%20Warning) The company states that this performance forecast is based on unaudited preliminary calculations, with final accurate financial data subject to the official H1 2025 report, and confirms no material uncertainties affecting the forecast's accuracy - This performance forecast data is unaudited and preliminary, investors should refer to the company's officially disclosed H1 2025 semi-annual report for final figures[7](index=7&type=chunk)[8](index=8&type=chunk) - The company declares no material uncertainties exist that would affect the accuracy of this performance forecast[7](index=7&type=chunk)

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has shown better performance than the market, with a year-to-date increase of 8.9%, outperforming the Shanghai Composite Index by 4.2 percentage points [4][16] - The global potash market is characterized by oligopoly, with major producers controlling supply and prices. Recent production cuts by key players are expected to sustain potash market conditions [5][27] - Phosphate supply remains tight, with stable prices and potential improvements in export opportunities as demand increases [5][27] Summary by Sections 1. Core Viewpoints - Policies are expected to improve supply-demand dynamics in the chemical sector, with a focus on cyclical investment opportunities [13] - The chemical industry is entering a new long-term prosperity cycle, driven by improved fundamentals and reduced risks [13][14] 2. Overall Performance of the Chemical Sector - The basic chemical industry index increased by 1.5% during the week, outperforming the Shanghai Composite Index by 0.4 percentage points [16] - Year-to-date, the basic chemical industry index has increased by 8.9%, significantly outperforming both the Shanghai Composite and ChiNext indices [16][18] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 298 stocks rose while 123 fell during the week [25] - The top performers included companies like Shangwei New Materials (+72.9%) and Hongbo New Materials (+24.7%) [25][26] 4. Key News and Company Announcements - The autumn fertilizer preparation has begun, with a focus on investment opportunities in potash and phosphate fertilizers [27] - Major potash producers have announced production cuts, which are expected to tighten supply and support prices [5][27] - Phosphate prices remain stable, with potential for improved export conditions as demand increases [5][27] 5. Product Price Changes - The report highlights significant price increases in various chemical products, with notable gains in dimethylamine (+16.7%) and fatty alcohol (+8.2%) [6] - Conversely, urea prices have seen a significant decline (-15%) [6]